Reports of anaphylaxis associated with the use of glatiramer acetate have prompted the Food and Drug Administration (FDA) to add a Boxed Warning to the prescribing information.

Most respondents were female (95 percent), self-diagnosed with TSW (84 percent), and reported current symptoms of AD and TSW. The researchers note that TSW was defined as dependence on topical ...

The Alabama Department of Public Health is investigating some reports of adverse reactions to injections of the antibiotic ceftriaxone, or Rocephin, but a local health provider said she has seen no ...

The FDA has advised health care professionals and patients with multiple sclerosis that treatment with glatiramer acetate is associated with a risk for anaphylaxis and issued a new boxed warning, ...

Teva Pharmaceutical’s Copaxone was approved by the FDA in 1996 to treat relapsing forms of MS, an autoimmune disorder that affects the central nervous system. Glatopa, a generic version of Teva’s ...